JP7840312B2 - 多重特異性結合性作用剤およびその使用 - Google Patents

多重特異性結合性作用剤およびその使用

Info

Publication number
JP7840312B2
JP7840312B2 JP2023507634A JP2023507634A JP7840312B2 JP 7840312 B2 JP7840312 B2 JP 7840312B2 JP 2023507634 A JP2023507634 A JP 2023507634A JP 2023507634 A JP2023507634 A JP 2023507634A JP 7840312 B2 JP7840312 B2 JP 7840312B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536631A5 (https=
JP2023536631A (ja
Inventor
ブライアン グレーザー，
ボニー ハマー，
シーマ カンタク，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2023536631A publication Critical patent/JP2023536631A/ja
Publication of JP2023536631A5 publication Critical patent/JP2023536631A5/ja
Application granted granted Critical
Publication of JP7840312B2 publication Critical patent/JP7840312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023507634A 2020-08-04 2021-08-03 多重特異性結合性作用剤およびその使用 Active JP7840312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061112P 2020-08-04 2020-08-04
US63/061,112 2020-08-04
PCT/US2021/044356 WO2022031710A2 (en) 2020-08-04 2021-08-03 Multispecific binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2023536631A JP2023536631A (ja) 2023-08-28
JP2023536631A5 JP2023536631A5 (https=) 2024-08-08
JP7840312B2 true JP7840312B2 (ja) 2026-04-03

Family

ID=80120131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507634A Active JP7840312B2 (ja) 2020-08-04 2021-08-03 多重特異性結合性作用剤およびその使用

Country Status (7)

Country Link
US (1) US20240010751A1 (https=)
EP (1) EP4192878A4 (https=)
JP (1) JP7840312B2 (https=)
CN (1) CN116390939A (https=)
AU (1) AU2021322114A1 (https=)
CA (1) CA3188068A1 (https=)
WO (1) WO2022031710A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3251615A1 (en) * 2022-01-31 2023-08-03 Centessa Pharmaceuticals (Uk) Limited Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses
WO2023245022A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target b7h3 and gd2 and uses thereof
AU2023383441A1 (en) * 2022-11-18 2025-06-05 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019095358A1 (zh) 2017-11-20 2019-05-23 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2019109876A1 (zh) 2017-12-04 2019-06-13 北京韩美药品有限公司 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) * 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
WO2022031680A1 (en) * 2020-08-04 2022-02-10 Exelixis, Inc. Cd47 binding agents and uses thereof
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019095358A1 (zh) 2017-11-20 2019-05-23 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
WO2019109876A1 (zh) 2017-12-04 2019-06-13 北京韩美药品有限公司 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Also Published As

Publication number Publication date
US20240010751A1 (en) 2024-01-11
WO2022031710A2 (en) 2022-02-10
AU2021322114A1 (en) 2023-03-02
EP4192878A4 (en) 2025-04-16
EP4192878A2 (en) 2023-06-14
CA3188068A1 (en) 2022-02-10
WO2022031710A3 (en) 2022-03-31
CN116390939A (zh) 2023-07-04
JP2023536631A (ja) 2023-08-28

Similar Documents

Publication Publication Date Title
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
JP2023528036A (ja) Ｔｉｇｉｔに対する抗体
CN119490599A (zh) 用于治疗癌症的dll3/cd3结合蛋白
JP2020515239A (ja) 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
JP2017535257A (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
US20250197502A1 (en) Multispecific binding agents and uses thereof
US20250326858A1 (en) 5t4 binding agents and uses thereof
US20230357391A1 (en) Cd47 binding agents and uses thereof
JP7854423B2 (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
CN118974098A (zh) 多重特异性结合剂及其用途
JP2024508764A (ja) 抗ｖｉｓｔａ抗体及びその使用
HK40119948A (zh) 与eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
EA049282B1 (ru) Антитела к tigit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260324

R150 Certificate of patent or registration of utility model

Ref document number: 7840312

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150